MiMedx Group (NASDAQ:MDXG) Downgraded by Wall Street Zen to Buy

MiMedx Group (NASDAQ:MDXG) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

MDXG has been the topic of a number of other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Cantor Fitzgerald lowered their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Citigroup started coverage on MiMedx Group in a research report on Monday. They issued a “market outperform” rating on the stock. Citizens Jmp started coverage on MiMedx Group in a report on Monday, February 23rd. They set a “market outperform” rating and a $10.00 price target for the company. Finally, UBS Group set a $10.00 price objective on MiMedx Group in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, MiMedx Group has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Down 1.0%

Shares of MiMedx Group stock opened at $4.89 on Friday. The firm has a market cap of $724.22 million, a price-to-earnings ratio of 15.28 and a beta of 1.59. The stock has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $6.58. MiMedx Group has a 52-week low of $4.78 and a 52-week high of $8.46. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analysts’ expectations of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%. On average, equities research analysts expect that MiMedx Group will post 0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

A number of hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC lifted its holdings in shares of MiMedx Group by 89.5% during the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after acquiring an additional 1,725,458 shares during the period. Nantahala Capital Management LLC acquired a new position in MiMedx Group in the third quarter worth about $10,237,000. Marshall Wace LLP lifted its stake in MiMedx Group by 864.9% during the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after purchasing an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the fourth quarter valued at approximately $7,134,000. Finally, Disciplined Growth Investors Inc. MN boosted its holdings in MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock valued at $9,656,000 after purchasing an additional 1,022,202 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.